Evidence map›Paper›PMID 39819032›Full record

Observational studyJournal of comparative effectiveness research2025

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab.

L Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L Johnetta BlakelyTennessee Oncology, Nashville, TN, USA.ORCID 0000-0001-6075-4937
Sabine OskarValue & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA.ORCID 0000-0002-8942-7734
Ian KudelVarian Medical Systems, Inc., Palo Alto, CA, USA.ORCID 0000-0003-1032-452X
Ashley RoushTennessee Oncology, Nashville, TN, USA.
Zoya ShamsiVarian Medical Systems, Inc., Palo Alto, CA, USA.
Toni PerryVarian Medical Systems, Inc., Palo Alto, CA, USA.
Annette ChristiansonVarian Medical Systems, Inc., Palo Alto, CA, USA.
Brittni SmithTennessee Oncology, Nashville, TN, USA.
Thomas BurkeValue & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA.ORCID 0000-0001-6335-0559

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsPatient Reported Outcome MeasuresAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumabelectronic patient-reported outcomeshealthcare resource usenon-small-cell lung cancerNoonaobservational studyreal-world time on treatmentreal-world time to next treatment or deathstandard of caresymptoms

Identifiers

PMID39819032
PMCPMC11773859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.